NASDAQ:TCDA Tricida Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tricida Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.05 -0.28 (-3.00 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$8.76Now: $9.05▼$9.3850-Day Range$9.33MA: $12.10▼$14.9752-Week Range$8.76Now: $9.05▼$44.30Volume1.18 million shsAverage Volume526,582 shsMarket Capitalization$452.94 millionP/E RatioN/ADividend YieldN/ABeta1.03 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingTricida has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.33, Tricida has a forecasted upside of 157.8% from its current price of $9.05.Amount of Analyst CoverageTricida has only been the subject of 3 research reports in the past 90 days. Previous Next 1.9 Community Rank Outperform VotesTricida has received 103 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTricida has received 169 “underperform” votes. (Add your “underperform” vote.)Community SentimentTricida has received 62.13% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Tricida and other stocks. Vote “Outperform” if you believe TCDA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TCDA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTricida does not currently pay a dividend.Dividend GrowthTricida does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tricida insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $213,920.00 in company stock.Percentage Held by Insiders70.40% of the stock of Tricida is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.12% of the stock of Tricida is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tricida are expected to grow in the coming year, from ($4.70) to ($4.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tricida is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tricida is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTricida has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.57 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TCDA Previous Symbol CUSIPN/A CIKN/A Webwww.tricida.com Phone415-429-7800Debt Debt-to-Equity Ratio0.83 Current Ratio11.52 Quick Ratio11.52Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.32 per share Price / Book1.70Profitability EPS (Most Recent Fiscal Year)($3.72) Net Income$-176,810,000.00 Net MarginsN/A Return on Equity-93.37% Return on Assets-61.36%Miscellaneous Employees76 Outstanding Shares50,049,000Market Cap$452.94 million Next Earnings Date11/12/2020 (Estimated) OptionableNot Optionable $9.05 -0.28 (-3.00 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive TCDA News and Ratings via Email Sign-up to receive the latest news and ratings for TCDA and its competitors with MarketBeat's FREE daily newsletter. Tricida (NASDAQ:TCDA) Frequently Asked Questions How has Tricida's stock been impacted by COVID-19? Tricida's stock was trading at $28.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TCDA stock has decreased by 67.7% and is now trading at $9.05. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Tricida? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tricida. When is Tricida's next earnings date? Tricida is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020. View our earnings forecast for Tricida. How were Tricida's earnings last quarter? Tricida Inc (NASDAQ:TCDA) released its quarterly earnings results on Wednesday, August, 5th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.46) by $0.30. View Tricida's earnings history. What price target have analysts set for TCDA? 3 brokerages have issued twelve-month price objectives for Tricida's shares. Their forecasts range from $10.00 to $40.00. On average, they expect Tricida's share price to reach $23.33 in the next year. This suggests a possible upside of 157.8% from the stock's current price. View analysts' price targets for Tricida. Who are some of Tricida's key competitors? Some companies that are related to Tricida include Aurinia Pharmaceuticals (AUPH), CryoPort (CYRX), Intra-Cellular Therapies (ITCI), Myovant Sciences (MYOV), Prestige Consumer Healthcare (PBH), Revance Therapeutics (RVNC), Eidos Therapeutics (EIDX), Uniqure (QURE), Kura Oncology (KURA), Cytokinetics (CYTK), Ligand Pharmaceuticals (LGND), Ironwood Pharmaceuticals (IRWD), Y-mAbs Therapeutics (YMAB), ALX Oncology (ALXO) and ZEALAND PHARMA/S (ZEAL). View all competitors. What other stocks do shareholders of Tricida own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Gilead Sciences (GILD), Pfizer (PFE), AT&T (T), Aphria (APHA), BioMarin Pharmaceutical (BMRN), CVS Health (CVS), General Motors (GM), Moderna (MRNA), Sorrento Therapeutics (SRNE) and AbbVie (ABBV). Who are Tricida's key executives? Tricida's management team includes the following people: Dr. Gerrit Klaerner, Founder, Pres, CEO & Exec. Director (Age 48)Mr. Geoffrey M. Parker, CFO & Sr. VP (Age 54)Dr. Dawn Parsell Ph.D., Sr. VP of Clinical Devel. (Age 57)Steffen Pietzke, VP of Fin. & Chief Accounting OfficerDr. Wilhelm Stahl, CTO & Sr. VP (Age 59) When did Tricida IPO? (TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO. What is Tricida's stock symbol? Tricida trades on the NASDAQ under the ticker symbol "TCDA." Who are Tricida's major shareholders? Tricida's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.24%), Cormorant Asset Management LP (1.74%), Point72 Asset Management L.P. (1.30%), Federated Hermes Inc. (0.76%), Artal Group S.A. (0.57%) and Opaleye Management Inc. (0.48%). Company insiders that own Tricida stock include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP and Wilhelm Stahl. View institutional ownership trends for Tricida. Which institutional investors are selling Tricida stock? TCDA stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Artal Group S.A., Engineers Gate Manager LP, Goldman Sachs Group Inc., California Public Employees Retirement System, Cormorant Asset Management LP, PDT Partners LLC, and Bank of America Corp DE. Company insiders that have sold Tricida company stock in the last year include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Gerrit Klaerner, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP, and Wilhelm Stahl. View insider buying and selling activity for Tricida. Which institutional investors are buying Tricida stock? TCDA stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Vanguard Group Inc., Jacobs Levy Equity Management Inc., New York State Common Retirement Fund, Federated Hermes Inc., Alyeska Investment Group L.P., Tekla Capital Management LLC, and Opaleye Management Inc.. Company insiders that have bought Tricida stock in the last two years include Geoffrey M Parker, and Orbimed Advisors Llc. View insider buying and selling activity for Tricida. How do I buy shares of Tricida? Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Tricida's stock price today? One share of TCDA stock can currently be purchased for approximately $9.05. How big of a company is Tricida? Tricida has a market capitalization of $452.94 million. The company earns $-176,810,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. Tricida employs 76 workers across the globe. What is Tricida's official website? The official website for Tricida is www.tricida.com. How can I contact Tricida? Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected] This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
